ArticleIranian journal of microbiology2025
Immunological efficiency of
Article in Iranian journal of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: Materials and Methods: PRP purification, LOS extraction, and endotoxin evaluation were performed using modified CY medium, hot phenol, and limulus amebocyte lysate methods, respectively. Rabbit groups were immunized with PRP (10 μg), dLOS (20 μg), and PRP-dLOS combine (10 μg+20 μg) three times on days 0, 14, and 28. Serum samples were acquired on days 0, 14, and 28 post-immunization, then IgM and IgG levels were assayed by enzyme-linked immunosorbent assay. Results: The concentrations of PRP, dLOS, and endotoxin were 1160 mg/L, 440 μg/mL, and 1450 EU/mL, respectively. PRP-dLOS combine led to a significant increase in IgG and IgM levels on days 14 and 28 post-immunization. After immunization with PRP-dLOS combine, serum levels of IgM and IgG increased from 16.8 to 29.3 μg/mL and 29.8 to 61.4 μg/mL, respectively from day 14 to day 28. Conclusion: PRP-dLOS combine is a promising approach for Hib management without the fear of delay in immune responses and interference with other vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.